Journal of Hematology & Oncology

We are pleased to announce two new Journal of Hematology & Oncology thematic series:

• Emerging agents and regimens for cancer therapy 2020: Research and review papers on novel agents, first-in-human clinical trials, and regimens for different cancer types will be considered. 
• Bi-specific T-cell engagers (BiTE) and antibody-drug conjugates (ADCs) for cancer therapy: Reviews, editorials, and first in-human clinical trial papers will be considered.

Authors interested in either series should submit a proposal to the Editorial Office.

Journal of Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology. Read more.

• A tertiary center experience of multiple myeloma patients with COVID-19
• Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis
• Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis

"Journal of Hematology & Oncology provides a forum for top-quality research and is a leading title in hematology and oncology, with an Impact Factor ranked in Q1 in both categories. The journal also publishes reviews and research highlights from leading experts in the field. Research is shared with fast turnaround times in an open access format among laboratory scientists, physician scientists, hematologists and oncologists."

Prof Delong Liu, Editor-in-Chief, Journal of Hematology & Oncology

Submit your research to our companion journal, Experimental Hematology & Oncology